Rocket Pharmaceuticals/$RCKT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rocket Pharmaceuticals
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Ticker
$RCKT
Sector
Primary listing
Employees
299
Headquarters
Website
RCKT Metrics
BasicAdvanced
$369M
-
-$2.49
0.65
-
Price and volume
Market cap
$369M
Beta
0.65
52-week high
$18.37
52-week low
$2.19
Average daily volume
2.3M
Financial strength
Current ratio
6.386
Quick ratio
6.256
Long term debt to equity
6.298
Total debt to equity
7.115
Interest coverage (TTM)
-139.85%
Profitability
EBITDA (TTM)
-253.866
Management effectiveness
Return on assets (TTM)
-38.07%
Return on equity (TTM)
-69.65%
Valuation
Price to book
1.04
Price to tangible book (TTM)
1.27
Price to free cash flow (TTM)
-1.713
Free cash flow yield (TTM)
-58.39%
Free cash flow per share (TTM)
-1.997
Growth
Earnings per share change (TTM)
-10.51%
3-year earnings per share growth (CAGR)
-5.66%
What the Analysts think about RCKT
Analyst ratings (Buy, Hold, Sell) for Rocket Pharmaceuticals stock.
Bulls say / Bears say
The FDA lifted the clinical hold on Rocket’s pivotal Phase 2 RP-A501 trial for Danon disease in August 2025, authorizing dosing at a recalibrated dose and allowing the company to resume advancement of its lead program (Reuters).
A 30% workforce reduction and other cost-saving measures implemented in Q2 2025 are projected to lower Rocket’s 12-month cash burn by nearly 25%, aligning resources with high-priority AAV cardiovascular gene therapy programs and extending operational runway into Q2 2027 (Business Wire).
The FDA granted RMAT designation to RP-A601 for PKP2-arrhythmogenic cardiomyopathy in July 2025, providing intensive FDA guidance and eligibility for expedited development and review pathways that could accelerate pivotal trial design and potential approval (Business Wire).
The FDA placed a clinical hold on Rocket’s pivotal Phase 2 RP-A501 trial for Danon disease following a patient’s death from capillary leak syndrome, delaying the lead program’s development timeline and increasing regulatory uncertainty (Reuters).
Rocket’s shares plunged 63% in premarket trading after the RP-A501 trial halt, reflecting severe investor skepticism about the safety and commercial viability of its lead gene therapy candidate (Reuters).
As part of its Q2 2025 reorganization, Rocket paused additional investments in its RP-L102 (Fanconi Anemia) and RP-L301 (Pyruvate Kinase Deficiency) programs, narrowing its pipeline and concentrating development risk on a limited set of AAV cardiovascular assets (Business Wire).
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
RCKT Financial Performance
Revenues and expenses
RCKT Earnings Performance
Company profitability
RCKT News
AllArticlesVideos
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire2 days ago
Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder
Reuters1 week ago
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rocket Pharmaceuticals stock?
Rocket Pharmaceuticals (RCKT) has a market cap of $369M as of October 12, 2025.
What is the P/E ratio for Rocket Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rocket Pharmaceuticals (RCKT) stock is 0 as of October 12, 2025.
Does Rocket Pharmaceuticals stock pay dividends?
No, Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Rocket Pharmaceuticals dividend payment date?
Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders.
What is the beta indicator for Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.